Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. AGIO
AGIO logo

AGIO

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

AGIO News

Agios Pharmaceuticals Under Investigation Following Phase 3 Trial Results, Stock Plummets

Apr 01 2026Newsfilter

Health Care Stocks Rise 2% Boosting Market

Mar 31 2026Yahoo Finance

Agios Pharmaceuticals Accelerates FDA Approval for Mitapivat

Mar 31 2026Fool

Agios Executive Sells Shares for Tax Obligation

Mar 31 2026Fool

Agios Pharmaceuticals' Mitapivat Gains FDA Attention for Sickle Cell Treatment

Mar 31 2026NASDAQ.COM

Agios Executive Sells Shares for Tax Payment

Mar 31 2026NASDAQ.COM

Agios Pharmaceuticals Seeks Accelerated Approval for Pyrukynd Expansion

Mar 31 2026seekingalpha

Agios Seeks Accelerated Approval for Mitapivat in Sickle Cell Disease

Mar 31 2026Newsfilter

Agios Pharmaceuticals' PYRUKYND Approved in UAE for Thalassemia Treatment

Mar 02 2026Yahoo Finance

Commodore Capital Fully Sells Agios Pharmaceuticals Shares

Feb 23 2026Fool

Rock Springs Capital Reduces Agios Holdings

Feb 17 2026Fool

Agios Pharmaceuticals Q4 2025 Earnings Call Insights

Feb 12 2026seekingalpha

Agios Pharmaceuticals Reports Q4 2025 Earnings and FDA Approval

Feb 12 2026seekingalpha

Agios Pharmaceuticals Reports Key 2025 Financial Highlights

Feb 12 2026Newsfilter

Agios Pharmaceuticals to Announce Q4 Earnings on February 12

Feb 11 2026seekingalpha

Key Earnings Reports and Economic Outlook This Week

Feb 08 2026CNBC